


SLIDER FRONT



SLIDER BACK



SLIDER CUTTER GUIDE



SLIDER FRONT

SLIDER BACK

SLIDE RULE FRONT

ASTHMA SLIDE RULE

1. Questions for prescriber/dispenser to ask themselves and a person with asthma

Using this slide rule, how much short-acting beta₂ agonist (SABA) also known as reliever/rescue/salbutamol/albuterol inhaler would you think was acceptable for a person with asthma to take in a year, week or day before you thought a review was necessary? What made you choose that?

	Increasing SABA use*											
Number of SABA inhalers Rx per year	1	2	3	4	5	6	7	8	9	10	11	12
Puffs of SABA used per year	200	400	600	800	1000	1200	1400	1600	1800	2000	2200	2400
Puffs of SABA used per week	4	8	12	15	19	23	27	31	35	39	42	46
Puffs of SABA used per day	< 1	1	2	2	3	>3	4	>4	5	6	>6	7
	Symptoms											

*Some devices do not contain 200 puffs. Check the number in the devices you prescribe/dispense or use, and modify these messages accordingly

Suggestion: Try asking a person with asthma question 1 after asking the ACTTM** question^{***}: During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol):

3 or more times per day / 1 or 2 times per day / 2 or 3 times per week / Once a week or less / Not at all

** Asthma Control TestTM *** https://getastmahelp.org/documents/ACT_AdultEng.pdf Asthma Right Care Guidance Notes available at www.iprcg.org/asthmarightcare





ASTHMA SLIDE RULE (reverse side: push slider back to left to begin)

2. Questions for prescriber to ask themselves and a person with asthma

Reflecting on your answer to Question 1, and using the number scale 0–10 below, slide to the number that reflects:

- How important is it that you organise a review? What made you select [number]?
What would have made it a higher number [eg 8]
- How confident do you feel to have a conversation about reducing the dose?
What made you select [number]? What would have made it a higher number [eg 8]?



For safety, the Global Strategy for Asthma Management and Prevention 2023 (www.ginasthma.org) does not recommend treatment of asthma in adults, adolescents and children 6–11 years with short-acting beta₂-agonists (SABA) alone. Instead, they should receive ICS-containing treatment to reduce their risk of serious exacerbations and to control symptoms. There is strong evidence that SABA-only treatment, although providing short-term relief of asthma symptoms, does not protect patients from severe exacerbations, and that regular or frequent use of SABA increases the risk of exacerbations.

Created and designed by IPCRG www.ipcr.org/aboutus

IPCRG received funding from AstraZeneca to develop the Asthma Right Care Initiative Updated June 2023



SLIDE RULE CUTTER GUIDE

